SEC Comment Letter for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Mar 12, 2013
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: March 12, 2013 · CIK: 0001137883 · Accession: 0000000000-13-013232
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-54365
Letter
March 12, 2013 Via E -mail Ms. Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics, Inc. 605 Third Avenue, 34th Floor New York, New York 10158
Re: Brainstorm Cell Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed on March 4, 2013 File No. 000-54365
Dear Ms. Sossover:
We have comple ted our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan for
Show Raw Text
March 12, 2013 Via E -mail Ms. Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics, Inc. 605 Third Avenue, 34th Floor New York, New York 10158 Re: Brainstorm Cell Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed on March 4, 2013 File No. 000-54365 Dear Ms. Sossover: We have comple ted our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan for Jeffrey P. Riedler Assistant Director cc: Via E -mail Thomas B. Rosedale, Esq. BRL Law Group LLC 425 Boylston Street, 3rd Floor Boston, Massachusetts 02116